Breaking News Instant updates and real-time market news.

AKRX

Akorn

$4.25

-1.34 (-23.97%)

06:14
12/10/18
12/10
06:14
12/10/18
06:14

Piper does not view Akorn as 'major fixer-upper,' keeps $9 target

Piper Jaffray analyst David Amsellem says he would not view Akorn (AKRX) as a "major fixer-upper" now that it is planning to move forward as a stand-alone company. Much of the pressure on EBITDA in recent years was a function of limited-competition products with brand-like margins, Amsellem tells investors in a research note. Further, the rest of Akorn's product portfolio appears to be stable, says the analyst. In addition, "high-quality" abbreviated new drug application approvals have been happening, "and that matters," argues Amsellem. He keeps an Overweight rating on Akorn with a $9 price target.

AKRX Akorn
$4.25

-1.34 (-23.97%)

12/07/18
CHLM
12/07/18
NO CHANGE
Target $11
CHLM
Buy
Craig-Hallum maintains Buy rating, $11 target on Akorn after Fresenius ruling
Craig-Hallum analyst Matt Hewitt said the Delaware Supreme Court ruling in favor of Fresenius (FSNUY) ends any hopes that a merger with Akorn (AKRX) will still occur, which may be a disappointment to some investors. However, it has been his view since the first ruling was announced that Akorn should be valued on a standalone basis. Akorn currently has a large pipeline of higher margin generics and the company's low-cost manufacturing facility in India has been idled due to the terms of the Fresenius agreement, but is likely to be brought online sometime in FY19 or FY20, Hewitt tells investors. He keeps a Buy rating and $11 price target on Akorn shares, which are down $1.34, or 24%, to $4.25 in afternoon trading.
11/27/18
PIPR
11/27/18
NO CHANGE
Target $9
PIPR
Overweight
Akorn approval an 'encouraging development,' says Piper Jaffray
Piper Jaffray analyst David Amsellem views Akorn's (AKRX) approval of its generic of Voltaren Gel as an "encouraging development." The news demonstrates that the company can execute on the approval of products on the more technically challenging end of the generics spectrum, Amsellem tells investors in a research note. The analyst believes Akorn is well positioned for "significant EBITDA recovery" over the next two years. He sees a "high likelihood" that the company in 2018 will have worked through the bulk of the erosion of key generics due to competition and a "relatively high" probability of meaningful cost reductions if it loses its appeal in its case against Fresenius (FSNUY). Amsellem reiterates an Overweight rating on Akorn with a $9 price target.
11/26/18
RBCM
11/26/18
NO CHANGE
RBCM
Sector Perform
Akorn gets FDA approval for generic Voltaren Gel, says RBC Capital
RBC Capital analyst Randall Stanicky said his "back and forth with management" at Akorn confirmed that the company received FDA approval for its generic version of Voltaren Gel, which the analyst notes represents the third ANDA approval from the company's Amityville facility since October. Stanicky, who continues to watch the company's ongoing litigation as well as its progress on the remediation of its Decatur and Somerset facilities, keeps a Sector Perform rating on Akorn shares.
10/17/18
10/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Infosys (INFY) upgraded to Market Perform from Underperform at William Blair WITH analyst Maggie Nolan citing Q2 results. 2. American Airlines (AAL), Delta Air Lines (DAL), and United Continental (UAL) upgraded to Buy from Hold at Deutsche Bank. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying based on trends associated with a number of its notable products, as well as his recent conversation with management, he believes a picture of sustainable EBITDA is emerging at Akorn that is better than what he had previously envisioned. 4. Workday (WDAY) upgraded to Outperform from Market Perform at Bernstein with analyst Mark Moerdler saying he determined that even if the ERP market moves reasonably slowly to the Cloud, it is large enough and the fact there are only a few vendors with a competitive SaaS solution should allow Workday to continue to gain share. 5. Domino's Pizza (DPZ) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying the pullback in the stock price is overdone and expects accelerated cost savings and solid comps to yield higher earnings, raising his FY20 EPS view to $12.01 from $11.72. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ARAV

Aravive

$11.82

5.13 (76.68%)

12:11
11/20/19
11/20
12:11
11/20/19
12:11
Recommendations
Aravive analyst commentary  »

Aravive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LK

Luckin Coffee

$26.78

-0.49 (-1.80%)

12:05
11/20/19
11/20
12:05
11/20/19
12:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

FCX

Freeport McMoRan

$11.32

0.035 (0.31%)

11:55
11/20/19
11/20
11:55
11/20/19
11:55
Options
Freeport McMoRan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
11/20/19
11/20
11:55
11/20/19
11:55
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

NEWT

Newtek Business Services

$23.09

-0.06 (-0.26%)

11:54
11/20/19
11/20
11:54
11/20/19
11:54
Hot Stocks
Newtek Business Services acquires majority stake in POS on Cloud »

Newtek Business Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTI

British American Tobacco

$36.93

-0.305 (-0.82%)

, MO

Altria Group

$47.77

0.83 (1.77%)

11:52
11/20/19
11/20
11:52
11/20/19
11:52
Hot Stocks
Cigarette makers rising after FDA said to shelve nicotine cut plans »

Shares of several makers…

BTI

British American Tobacco

$36.93

-0.305 (-0.82%)

MO

Altria Group

$47.77

0.83 (1.77%)

PM

Philip Morris

$84.15

0.7 (0.84%)

IMBBY

Imperial Brands

$0.00

(0.00%)

XXII

22nd Century

$1.44

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.52

-0.37 (-0.12%)

11:51
11/20/19
11/20
11:51
11/20/19
11:51
General news
Trump says still talking to China, who wants to make deal »

President Trump said on…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$311.52

-0.37 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

11:49
11/20/19
11/20
11:49
11/20/19
11:49
Periodicals
New 'Pokemon' sells 1.365M units in Japan in first three days, Famitsu says »

Nintendo's latest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$104.76

6.77 (6.91%)

11:48
11/20/19
11/20
11:48
11/20/19
11:48
Hot Stocks
Breaking Hot Stocks news story on Alnylam »

Alnylam trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Feb

BTI

British American Tobacco

$36.83

-0.405 (-1.09%)

, MO

Altria Group

$47.71

0.77 (1.64%)

11:47
11/20/19
11/20
11:47
11/20/19
11:47
Periodicals
FDA shelves plan to require sharp cut in nicotine in cigarettes, Bloomberg says »

Bloomberg reported that a…

BTI

British American Tobacco

$36.83

-0.405 (-1.09%)

MO

Altria Group

$47.71

0.77 (1.64%)

PM

Philip Morris

$84.12

0.67 (0.80%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

GOOGL

Alphabet Class A

$1,306.83

-5.76 (-0.44%)

, GOOG

Alphabet

$1,308.00

-6.71 (-0.51%)

11:45
11/20/19
11/20
11:45
11/20/19
11:45
Periodicals
Some who pre-ordered Google Stadia still can't access service, Kotaku says »

Some customers who…

GOOGL

Alphabet Class A

$1,306.83

-5.76 (-0.44%)

GOOG

Alphabet

$1,308.00

-6.71 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPC

Marathon Petroleum

$61.17

-0.67 (-1.08%)

11:45
11/20/19
11/20
11:45
11/20/19
11:45
Options
Marathon Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
11/20/19
11/20
11:45
11/20/19
11:45
General news
Treasury's $15 B 16-day cash management bill (CMB) stopped at 1.540% »

Treasury's $15 B…

VZ

Verizon

$59.19

-0.31 (-0.52%)

11:39
11/20/19
11/20
11:39
11/20/19
11:39
Hot Stocks
Verizon and Respond unveil third 5G First Responder Lab cohort »

Verizon, in partnership…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 30

    Jan

AMRN

Amarin

$20.18

-2.56 (-11.26%)

, BRY

Berry Petroleum

$7.13

-1.77 (-19.89%)

11:39
11/20/19
11/20
11:39
11/20/19
11:39
On The Fly
Bearish view of Amarin, Berry downgrades among today's top analyst calls »

Check out today's top…

AMRN

Amarin

$20.18

-2.56 (-11.26%)

BRY

Berry Petroleum

$7.13

-1.77 (-19.89%)

TW

Tradeweb Markets

$44.64

1.38 (3.19%)

CBOE

Cboe Global Markets

$121.85

-0.68 (-0.55%)

CGC

Canopy Growth

$17.43

2.11 (13.77%)

I

Intelsat

$7.38

1.3 (21.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 28

    Dec

SYBT

S.Y. Bancorp

$40.66

-0.04 (-0.10%)

11:37
11/20/19
11/20
11:37
11/20/19
11:37
Hot Stocks
S.Y. Bancorp increases quarterly dividend 4% »

Stock Yards Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

HUYA

Huya

$21.90

-0.59 (-2.62%)

11:35
11/20/19
11/20
11:35
11/20/19
11:35
Options
HUYA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

UBER

Uber

$28.35

1.32 (4.88%)

11:25
11/20/19
11/20
11:25
11/20/19
11:25
Options
Uber call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

SQ

Square

$67.18

0.75 (1.13%)

, PYPL

PayPal

$104.73

-0.21 (-0.20%)

11:25
11/20/19
11/20
11:25
11/20/19
11:25
Conference/Events
Wedbush payments/IT services analyst to hold an advisor luncheon »

Payments/IT Services…

SQ

Square

$67.18

0.75 (1.13%)

PYPL

PayPal

$104.73

-0.21 (-0.20%)

WP

Worldpay

$0.00

(0.00%)

GPN

Global Payments

$181.54

-0.21 (-0.12%)

TSS

TSYS

$0.00

(0.00%)

FDC

First Data

$0.00

(0.00%)

EVOP

EVO Payments

$27.31

-0.19 (-0.69%)

IIIV

i3 Verticals

$23.04

0.19 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 09

    Dec

  • 10

    Dec

  • 07

    Jan

  • 08

    Jan

  • 26

    Feb

GNPX

Genprex

$0.52

-0.0986 (-15.90%)

11:20
11/20/19
11/20
11:20
11/20/19
11:20
Syndicate
Genprex annoucnes $1.26M registered direct offering »

Genprex announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$27.21

0.315 (1.17%)

11:20
11/20/19
11/20
11:20
11/20/19
11:20
Recommendations
Teradata analyst commentary  »

Teradata interim CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/20/19
11/20
11:17
11/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$20.18

-0.02 (-0.10%)

11:16
11/20/19
11/20
11:16
11/20/19
11:16
Initiation
Nielsen initiated  »

Nielsen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/20/19
11/20
11:16
11/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$43.50

-0.22 (-0.50%)

11:15
11/20/19
11/20
11:15
11/20/19
11:15
Options
Foot Locker put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.